

# **TCT Pharmacist Conference at the 2021 TCT Meetings of ASTCT and CIBMTR Digital Experience**

## **February 10–11, 2021**

### **Target Audience**

This activity is intended for clinical pharmacists, residents, and nurses who specialize in or are training in blood and marrow transplantation (BMT).

### **Accredited Provider**

Jointly provided by The France Foundation and the American Society for Transplantation and Cellular Therapy



### **Program Overview**

The TCT Pharmacists Conference is a 2-day session held annually in conjunction with the TCT Meetings of ASTCT and CIBMTR. This conference features leaders of the pharmacy profession specializing in HCT and cellular therapy, along with their colleagues and experts from other medical disciplines, who provide perspective and an evidence-based approach to the emerging issues and clinical management of this complex patient population.

### **Overall Program Learning Objectives**

- Discuss current clinical practice and challenges for pharmacists in the field of blood and marrow transplantation (BMT) and cellular therapy.
- Identify best practice strategies and clinical challenges related to pre- and post-transplant myelofibrosis, sickle cell disease, CAR-T therapies for solid tumors, CAR-T toxicity, pharmacogenetics, CMV management, transplant-associated thrombotic microangiopathy, and disease post-allogeneic HCT.
- Examine challenging patient cases related to donor specific antibodies, palliative care in transplant, and stem cell transplants in transgendered patients.
- Analyze strategies for BMT-related pharmacy research opportunities and discuss findings from current, evidence-based research
- Identify challenges and strategies for managing critically ill BMT patients throughout the COVID-19 crisis.

### **2021 TCT Pharmacist Conference Program Planning Committee**

<b>Tatjana Grgic, PharmD, BCOP, CPP (2021 Chair)</b> University of North Carolina	<b>Kelsey Konrardy, PharmD</b> University of Kansas Health System
<b>Kathy Hogan Edwards, PharmD, BCPS</b> MUSC Health Charleston	<b>Sarah Perreault, PharmD</b> Yale New Haven Health
<b>Craig Freyer, PharmD, BCOP</b> Hospital of the University of Pennsylvania	<b>Jamie Rouch, PharmD, BCPPS</b> Children's Mercy Kansas City
<b>Rebecca Gonzalez, PharmD, BCOP</b>	<b>Terri Lynn Shigle, PharmD, BCPS, BCOP</b>

<b>Moffitt Cancer Center</b>	<b>The University of Texas MD Anderson Cancer Center</b>
<b>Breana Goscicki, PharmD, BCPPS</b> UPMC Children's Hospital of Pittsburgh	<b>Teresa Thakrar, PharmD, BCOP</b> Indiana University Health
<b>Victoria Handy, PharmD, BCOP</b> The University of Texas MD Anderson Cancer Center	<b>Nicole Watts, PharmD, BCOP</b> University of Alabama Medical Center
<b>Ekaterina Kachur, PharmD, BCOP</b> Atrium Health	

**Activity Agenda & Faculty**  
**2021 TCT Pharmacists Conference Schedule**

<b>Time</b>	<b>Presentation</b>	<b>Speaker</b>	<b>UAN</b>	<b>Hours (CEUs)</b>
<b>Day 1 (total = 6.25 CE)</b>				
8:30- 8:45 (15 min)	Welcome/Overview 2021 Pharmacy Conference	Tatjana Grgic, PharmD Tatjana.grgic@unchealth.unc.edu		
8:45-9:15 (30 min)	Myelofibrosis I: Pre-Transplant Therapy, Indications for Transplant, and Optimal Donor Source	Whitney D. Wallis, PharmD wdwallis@mdanderson.org	0391-9999-21-001-L01-P	0.5
9:15-9:45 (30 min)	Transplant Considerations for Myelofibrosis: Conditioning Regimen Selection, Toxicity Considerations, and Post Transplant Management	Craig W. Freyer, PharmD craig.freyer@gmail.com	0391-9999-21-002-L01-P	0.5
9:45-10:15 (30 min)	ASTCT Pharmacy Special Interest Group (SIG) Update 2020-2021	Maurice Alexander, PharmD Maurice.alexander@unchealth.unc.edu	0391-9999-21-003-L01-P	0.5
10:15-10:30 (15 min)	Morning Break			
10:30-11:15 (45 min)	Emerging Landscape of Hematopoietic Stem cell Transplant and Gene Therapy for Sickle Cell Disease: Cure without Complication on the Horizon	Hemalatha Rangarajan, MD hemalatha.rangarajan@nationwidechildrens.org	0391-9999-21-004-L01-P	0.75
11:15-12:00 (45 min)	CAR T cell for Solid Tumors	Kathryn Culos, PharmD katie.culos@vumc.org	0391-9999-21-005-L01-P	0.75
12:00-1:15 (75 min)	Lunch Break			
1:15-1:45 (30 min)	Challenging Cases: Donor-specific Antibodies (DSAs)	Amanda Brahim, PharmD abraham@mhs.net	0391-9999-21-006-L01-P	0.5
1:45-2:30 (45 min)	Updates from the American Society of Hematology Annual Meeting 2020: Part I	Cynthia Herrera, BCOP, PharmD cynthia.herrera@nm.org	0391-9999-21-007-L01-P	0.75

2:30-2:45 (15 min)	Afternoon Break			
2:45-3:30 (45 min)	Updates from the American Society of Hematology Annual Meeting 2020: Part II	Daniel Wojenski, PharmD dwojensk@nm.org	0391-9999-21-008-L01-P	0.75
3:30-4:00 (30 min)	Transplant-Associated Thrombotic Microangiopathy (TA-TMA)	Breana Goscicki, PharmD, BCPPS breana.goscicki@upmc.edu	0391-9999-21-009-L01-P	0.5
4:00-4:15 (15 min)	Afternoon Break			
4:15-5:30 (75 min)	NIA Grant Winner Update and Best Abstract Presentations	Justin Arnall, PharmD - justin.arnall@atriumhealth.org  Jing Zhu, PharmD daisy23@email.unc.edu  Issam Hamadeh, PharmD ish_tox@yahoo.com  Grace Elsey, PharmD gelsey@wakehealth.edu  Jason Barreto, PharmD barreto.jason@mayo.edu	0391-9999-21-011-L01-P	1.25

Time	Presentation	Speaker	UAN	Hours (CEUs)
<b>Day 2 (total = 6.75 CE)</b>				
8:30-8:45 (15 min)	Welcome/Overview 2021 TCT Pharmacy Conference	Rebecca Gonzalez, PharmD (Moffitt) Rebecca.Gonzalex@moffitt.org		
8:45-9:15 (30 min)	Palliative Care in Patients Following Hematopoietic Stem Cell Transplant (HCT)	Chelsea Minor, PharmD, BCPS, BCOP chelsea.minor@wustl.edu	0391-9999-21-012-L01-P	0.5
9:15-10:15 (60 min)	Grant writing strategies for pharmacists	Paul Armistead, MD, PhD paul_armistead@med.unc.edu	0391-9999-21-013-L01-P	1
10:15-10:30 (15 min)	Morning Break			
10:30-11:15 (45 min)	Ensuring the Cure is Not Worse Than the Disease Itself: Updates in Toxicity Management and Optimization of CAR T-cells in Hematologic Malignancies	Colleen Timlin, PharmD colleen.timlin@uphs.upenn.edu	0391-9999-21-014-L01-P	0.75
11:15-12:00 (45 min)	Detecting and managing disease after allogeneic HCT in MDS/AML	Michael Byrne, MD michael.byrne@vumc.org	0391-9999-21-015-L01-P	0.75
12:00-1:15 (75 min)	Lunch Break			

1:15- 1:45 (30 min)	Updates in CMV Management	Terri Lynn Shigle, PharmD, BCOP tshigle@mdanderson.org	0391-9999-21-016-L01-P	0.5
1:45- 2:15 (30 min)	Pharmacogenomics: Implications in Stem Cell Transplant Patients	J. Kevin Hicks, PharmD, PhD james.hicks@moffitt.org	0391-9999-21-017-L01-P	0.5
2:15-2:30 (15 min)	Afternoon Break			
2:30-3:00 (30 min)	Stem Cell Transplant in the Transgender Patient	Erin Barthelmess, PharmD erin.barthelmess@childrenscolorado.org	0391-9999-21-018-L01-P	0.5
3:00-4:00 (60 min)	GVHD: Tapering of Immunosuppression in Prophylactic and Treatment Setting	Rohtesh S. Mehta, MD rmehta1@mdanderson.org	0391-9999-21-019-L01-P	1
4:00-4:15 (15 min)	Afternoon Break			
4:15-5:30 (75 min)	Best Practice Discussion: Patient Management during COVID-19 Pandemic	Zahra Mahmoudjafari, PharmD, BCOP zmahmoudjafari@kumc.edu  Andrew Lin, PharmD lina@mskcc.org  Julianna Roddy, PharmD, BCOP julianna.rodny@gmail.com	0391-9999-21-020-L01-P	1.25



### **Accreditation - Pharmacists**

The France Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education and will award up to 13.0 CEUs to pharmacists who complete the activity and evaluation forms. There are both knowledge-based and application-based sessions in this activity. Please see the agenda above for a listing of the ACPE Universal Activity Numbers (UANs) associated with each session.

Your CE credits will be submitted electronically to the CPE Monitor. CE providers must upload participant information within 60 days from the date the participant completed the live activity. **Please submit all evaluations and credit requests no later than March 12, 2021 to ensure your credit fulfillment. CE credit cannot be awarded past 60 days from the activity date.**

### **METHOD OF PARTICIPATION/HOW TO RECEIVE CREDIT**

1. There are no fees for participating in and receiving credit for this activity.
2. Review the activity objectives and CE information.
3. Participate in the CE activity.
4. Complete the CE evaluation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
5. If you are requesting ACPE pharmacy credit—your CE credits will be submitted electronically to the CPE Monitor.

### **Disclosure Policy**

The France Foundation (TFF) and The American Society for Transplantation and Cellular Therapy (ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.

### **Activity Staff Disclosures**

The planners, reviewers, editors, staff, CE committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

The planners, reviewers, editors, staff, CE committee, or other members at The American Society for Transplantation and Cellular Therapy who control content have no relevant financial relationships to disclose.

### **Faculty Disclosures – Program Planning Committee**

The faculty listed below report that they have no relevant financial relationships to disclose:

- Tatjana Grgic
- Ekaterina Kacher
- Breana Goscicki
- Jamie Rouch
- Kathy Hogan Edwards
- Kelsey Knorardy
- Rebecca Gonzalez
- Sarah Perreault
- Teresa Thakrar
- Terri Lynn Shigle
- Victoria Handy

The following faculty report that they have relevant financial relationships to disclose:

- Craig Freyer reports that he has done non-CE consulting for Astellas and Incyte; participated in a non-CE speakers bureau for Astellas; owns stocks in Bluebird Bio and Janssen; and his spouse/partner is employed by Janssen
- Nicole Watts reports that her spouse/partner is a share/stockholder of Gilead

### **Faculty Disclosures–Activity Faculty**

The faculty listed below report that they have no relevant financial relationships to disclose:

- Erin Barthelmess, PharmD
- Grace Elsey, PharmD
- Rebecca Gonzalez, PharmD
- Breana Goscicki, PharmD, BCPPS
- Tatjana Grgic, PharmD
- Issam Hamadeh, PharmD
- Cynthia Herrera, BCOP, PharmD
- Zahra Mahmoudjafari, PharmD, BCOP
- Chelsea Minor, PharmD, BCPS, BCOP
- Hemalatha Rangarajan, MD

- Terri Lynn Shigle, PharmD, BCOP
- Colleen Timlin, PharmD
- Whitney D. Wallis, PharmD
- Daniel Wojenski, PharmD
- Jing Zhu, PharmD

The following faculty report that they have relevant financial relationships to disclose:

- Maurice Alexander reports non-CE consulting for AcelRx
- Paul Armistead reports non-CE Consulting for GeneCentric and receipt of Intellectual Property Rights /Patent Holder with Cell Microsystems
- Justin Arnall reports non-CE Consulting for Novo Nordisk and CSL Behring
- Amanda Brahim reports a salary or employment relationship with Janssen
- Jason Barreto reports contract Research for Astellas Pharma Global Development, Inc
- Michael Byrne reports non-CE Consulting for Celgene/Celularity (DSMB) and Concert Pharmaceuticals (DSMB, Consulting); and contract research Karyopharm (Research Funding)
- Katie Culos reports non-CE Consulting for Jazz Pharmaceuticals and Incyte
- Craig Freyer reports non-CE consulting for Astellas and Incyte; participated in a non-CE speakers bureau for Astellas; owns stocks in Bluebird Bio and Janssen; and his spouse/partner is employed by Janssen
- J. Kevin Hicks reports non-CE consulting for Novartis, Quest, and 23andMe; contract research for OneOme
- Andrew Lin reports non-CE consulting for Incyte
- Rohtesh S. Mehta reports contract research for Incyte, Kadmon, and CSL Behring
- Julianna V.F. Roddy reports non-CE speakers bureau for Astellas and a salary or employment relationship for Merck Research Labs

#### **Disclosure of Unlabeled Use**

The France Foundation (TFF) and The American Society for Transplantation and Cellular Therapy (ASTCT) require CE faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

#### **Commercial Support Acknowledgment**

This activity is supported by a educational grants from Amgen, Merck, and Jazz Pharmaceuticals.

#### **Disclaimer**

The France Foundation and the American Society for Transplantation and Cellular Therapy present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation The American Society for Transplantation and Cellular Therapy, and the commercial supporter(s) assume no liability for the information herein.